Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 117
Filter
1.
Environ Res ; 199: 111282, 2021 08.
Article in English | MEDLINE | ID: mdl-34015296

ABSTRACT

BACKGROUND: Residential exposure to pesticides may occur via inhalation of airborne pesticides, direct skin contacts with pesticide-contaminated surfaces, and consumption of food containing pesticide residues. The aim was to study the association of dermal exposure to pesticides between the use and non-use periods, between farmer and non-farmer families and between dermal exposure and the excretion of metabolites from urine in residents living close to treated agricultural fields. METHODS: In total, 112 hand wipes and 206 spot urine samples were collected from 16 farmer and 38 non-farmer participants living within 50 m from an agricultural field in the Netherlands. The study took place from May 2016 to December 2017 during the use as well as the non-use periods of pesticides. Hand wipes were analysed for the parent compound and urines samples for the corresponding urinary metabolite of five applied pesticides: asulam, carbendazim (applied as thiophanate-methyl), chlorpropham, prochloraz and tebuconazole. Questionnaire data was used to study potential determinants of occurrence and levels of pesticides in hand wipes according to univariate and multivariate analysis. RESULTS: Carbendazim and tebuconazole concentrations in hand wipes were statistically significantly higher in the pesticide-use period compared to the non-use period. In addition, especially during the use periods, concentrations were statistically significantly higher in farmer families compared to non-farmer families. For asulam, chlorpropham and prochloraz, the frequency of non-detects was too high (57-85%) to be included in this analysis. The carbendazim contents in urine samples and hand wipes were correlated on the first and second day after taking the hand wipe, whereas chlorpropham was only observed to be related on the second day following the spray event. CONCLUSIONS: Concentrations in hand wipes were overall higher in pesticide use periods compared to non-use periods and higher in farmer families compared to non-farmer families. Only for carbendazim a strong correlation between concentrations in hand wipes and its main metabolite in urine was observed, indicating dermal exposure via contaminated indoor surfaces. We expect this to be related to the lower vapour pressure and longer environmental lifetime of carbendazim compared to the other pesticides studies.


Subject(s)
Pesticide Residues , Pesticides , Biomarkers , Environmental Exposure/analysis , Environmental Monitoring , Hand , Humans , Netherlands , Pesticides/analysis
2.
Placenta ; 104: 220-231, 2021 01 15.
Article in English | MEDLINE | ID: mdl-33429119

ABSTRACT

INTRODUCTION: An increasing number of women becomes pregnant while suffering from chronic kidney disease (CKD). As a result of decreased renal function, uremic solutes circulate at high levels in the maternal circulation. This study aimed to acquire more knowledge about the placental transfer of uremic solutes across the human placenta. METHODS: Placental transfer was studied in healthy term placentas, via the ex vivo dual-side human cotyledon perfusion technique (closed-closed set-up for both maternal and fetal circulations). Uremic solute concentrations in maternal and fetal perfusates were measured via LC-MS/MS over 180 min of perfusion. RESULTS: We found that the studied compounds demonstrated different degrees of placental transfer. Fetal-to-maternal perfusate ratios at t = 180 min were for anthranilic acid 1.00 ± 0.02, indole-3-acetic acid 0.47 ± 0.08, hippuric acid 0.36 ± 0.18, l-arabinitol 0.33 ± 0.04, indoxyl sulfate 0.33 ± 0.11, neopterin 0.28 ± 0.14 and kynurenic acid 0.13 ± 0.03. All uremic solutes studied also emerged in the perfusates when cotyledons were perfused in the absence of uremic solute concentrations added to the maternal reservoir. For kynurenin these concentrations were so high, it complicated the calculation of a transfer ratio for the exogenously administered compound. DISCUSSION: After 180 min of exposure the extent of placental transfer differs substantially for the solutes studied, reflecting different transfer rates. Future studies should investigate to what extent specific uremic solutes reach the fetal circulation in vivo and how they may interfere with organ function and development of the unborn child.


Subject(s)
Cotyledon/metabolism , Placenta/metabolism , Uremic Toxins/metabolism , Biological Transport , Chromatography, Liquid , Female , Humans , Pregnancy , Tandem Mass Spectrometry
3.
Histochem Cell Biol ; 154(3): 265-273, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32448916

ABSTRACT

When drugs exert their effects in the brain, linear extrapolation of doses from adults could be harmful for children as the blood-brain barrier (BBB) and blood-CSF barrier (BCSFB) function is still immature. More specifically, age-related variation in membrane transporters may impact brain disposition. As human data on brain transporter expression is scarce, age dependent [gestational age (GA), postnatal age (PNA), and postmenstrual age (PMA)] variation in immunohistochemical localization and staining intensity of the ABC transporters P-glycoprotein (Pgp), breast cancer resistance protein (BCRP), and multidrug resistance-associated proteins 1, 2, 4, and 5 (MRP1/2/4/5) was investigated. Post mortem brain cortical and ventricular tissue was derived from 23 fetuses (GA range 12.9-39 weeks), 17 neonates (GA range 24.6-41.3 weeks, PNA range 0.004-3.5 weeks), 8 children (PNA range 0.1-3 years), and 4 adults who died from a wide variety of underlying conditions. In brain cortical BBB, immunostaining increased with age for Pgp and BCRP, while in contrast, MRP1 and MRP2 staining intensity appeared higher in fetuses, neonates, and children, as compared to adults. BCSFB was positively stained for Pgp, MRP1, and MRP2 and appeared stable across age, while BCRP was not detected. MRP4 and MRP5 were not detected in BBB or BCSFB. In conclusion, human BBB and BCSFB ABC membrane transporters show brain location and transporter-specific maturation.


Subject(s)
ATP-Binding Cassette Transporters/biosynthesis , Blood-Brain Barrier/metabolism , ATP-Binding Cassette Transporters/analysis , ATP-Binding Cassette Transporters/cerebrospinal fluid , Adult , Child, Preschool , Humans , Immunohistochemistry , Infant
4.
Arch Toxicol ; 93(9): 2545-2553, 2019 09.
Article in English | MEDLINE | ID: mdl-31359083

ABSTRACT

Tebuconazole (TEB) is a widely used triazole fungicide, but the toxicokinetics of its human metabolites are not fully described. For proper interpretation of biological monitoring data, knowledge on the metabolism and elimination of the compound is required. A human volunteer study was performed with the aim to describe the time courses of urinary excretion after controlled oral and dermal administration of TEB. Six healthy volunteers (three males and three females) received on separate occasions a single oral dose of 1.5 mg of TEB and a single dermal dose of 2.5 mg during 1 h. In addition to a pre-exposure urine sample, complete urine voids were collected over 48 h post-administration. The main metabolite hydroxy-tebuconazole (TEB-OH) was quantified in each urine sample. Peak excretion rates after oral and dermal administration were reached after 1.4 and 21 h, mean elimination half-lives were 7.8 and 16 h, and recoveries within 48 h were 38% and 1%, respectively. The time courses of excretion were compared to simulations with an established physiologically based toxicokinetic model for TEB that was extended with a parallel model for TEB-OH. Overall, TEB-OH was rapidly excreted into urine after oral exposure, and renal elimination was considerably slower after dermal exposure. Urinary time courses between individuals were similar. The model predictions were in good agreement with the observed time courses of excretion.


Subject(s)
Fungicides, Industrial , Models, Biological , Triazoles , Administration, Cutaneous , Administration, Oral , Adult , Female , Fungicides, Industrial/administration & dosage , Fungicides, Industrial/toxicity , Fungicides, Industrial/urine , Healthy Volunteers , Humans , Male , Toxicokinetics , Triazoles/administration & dosage , Triazoles/toxicity , Triazoles/urine , Young Adult
5.
Toxicol Lett ; 298: 201-206, 2018 Dec 01.
Article in English | MEDLINE | ID: mdl-30292883

ABSTRACT

Young children differ from adults in their exposure and susceptibility to environmental chemicals (e.g. pesticides) because of various factors such as behavior, diet and physiology. Their heightened vulnerability to environmental stressors makes it important to obtain appropriate urine samples for exposure characterization. However, collecting urine from non-toilet-trained children has been shown to be methodologically and practically challenging. Four urine collection approaches were tested: a disposable diaper, a urine bag, a collection pad and the clean catch. The success rate and the user rating of each method was evaluated. The success rates were 67%, 21%, 17% and 4% for the disposable diaper, urine bag, collection pad and clean catch, respectively. The average user ratings on a 0-10 (0 = inconvenient, 10 = convenient) scale were 9.0, 4.7, 7.3 and 2.5, respectively. Subsequently, the best rated method, the disposable polyacrylate diaper was tested with hydroxy-tebuconazole as an exposure biomarker for the fungicide tebuconazole and creatinine for urine density adjustment. After LC-MS/MS analysis, the recoveries of hydroxy-tebuconazole in the range of 0.05-25 ng/mL were on average 106%, and for creatinine 87%. Precisions (relative standard deviation) were for both 3%. The overall procedure including collection and extraction was assessed, resulting in three out of seven positive samples. Based on this study, the disposable diaper is a suitable method for urine collection of non-toilet-trained children for biomonitoring of tebuconazole. This method can serve as a basis for extension to other substances of interest.


Subject(s)
Diapers, Infant , Environmental Monitoring/methods , Environmental Pollutants/urine , Fungicides, Industrial/urine , Renal Elimination , Toilet Training , Triazoles/urine , Urine Specimen Collection , Biotransformation , Child, Preschool , Environmental Biomarkers , Environmental Exposure/adverse effects , Environmental Pollutants/adverse effects , Female , Fungicides, Industrial/adverse effects , Humans , Hydroxylation , Infant , Infant, Newborn , Male , Pilot Projects , Reproducibility of Results , Risk Assessment , Triazoles/adverse effects , Urinalysis
6.
BJS Open ; 2(4): 220-228, 2018 Aug.
Article in English | MEDLINE | ID: mdl-30079391

ABSTRACT

BACKGROUND: Diclofenac increases the risk of anastomotic leakage, but the underlying mechanism is unknown. As diclofenac is excreted largely as biliary metabolites, the aim of this study was to determine the effect of these metabolites on intestinal anastomoses. METHODS: This was a randomized controlled blinded experiment using 210 male Wistar rats to assess the effect of 'diclofenac bile' on the anastomotic complication score, leak rate and anastomotic strength following oral and parenteral administration of diclofenac. Bile duct and duodenal catheterization techniques were used for diversion and replacement of bile, and biliary diclofenac metabolites were determined. RESULTS: Replacement of control bile with diclofenac bile resulted in higher anastomotic complication scores (P = 0·006) and leakage in five of 18 animals, compared with one of 18 controls (P = 0·089). In turn, following oral diclofenac administration, replacement of diclofenac bile with control bile reduced anastomotic complications (P = 0·016). The leak rate was seven of 15 versus 13 of 17 without replacement (P = 0·127). After intramuscular administration of diclofenac, the reduction in anastomotic complications was not significant when bile was replaced with control bile (P = 0·283), but it was significant when bile was drained without replacement (P = 0·025). Diclofenac metabolites in bile peaked within 2 h after administration. Administration of diclofenac bile resulted in nearly undetectable plasma levels of diclofenac (mean(s.d.) 0·01(0·01) µg/ml) after 120 min. Following oral diclofenac, bile replacement with control bile did not affect the plasma concentration of diclofenac (0·12(0·08) µg/ml versus 0·10(0·05) µg/ml with diclofenac bile; P = 0·869). CONCLUSION: Altered bile composition as a result of diclofenac administration increases the ileal anastomotic complication rate in rats.

7.
Eur J Pharm Sci ; 119: 244-248, 2018 Jul 01.
Article in English | MEDLINE | ID: mdl-29655601

ABSTRACT

Currently, tacrolimus is the most potent immunosuppressive agent for renal transplant recipients and is commonly prescribed during pregnancy. As data on placental exposure and transfer are limited, we studied tacrolimus placental handling in samples obtained from renal transplant recipients. We found transfer to venous umbilical cord blood, but particularly noted a strong placental accumulation. In patient samples, tissue concentrations in a range of 55-82 ng/g were found. More detailed ex vivo dual-side perfusions of term placentas from healthy women revealed a tissue-to-maternal perfusate concentration ratio of 113 ±â€¯49 (mean ±â€¯SEM), underlining the placental accumulation found in vivo. During the 3 h ex vivo perfusion interval no placental transfer to the fetal circulation was observed. In addition, we found a non-homogeneous distribution of tacrolimus across the perfused cotyledons. In conclusion, we observed extensive accumulation of tacrolimus in placental tissue. This warrants further studies into potential effects on placental function and immune cells of the placenta.


Subject(s)
Immunosuppressive Agents/pharmacokinetics , Kidney Transplantation , Placenta/metabolism , Tacrolimus/pharmacokinetics , Adult , Female , Humans , Perfusion , Pregnancy
8.
Sci Rep ; 7(1): 10623, 2017 09 06.
Article in English | MEDLINE | ID: mdl-28878224

ABSTRACT

Septic acute kidney injury (AKI) associates with poor survival rates and often requires renal replacement therapy. Glucocorticoids may pose renal protective effects in sepsis via stimulation of mitochondrial function. Therefore, we studied the mitochondrial effects of dexamethasone in an experimental inflammatory proximal tubule epithelial cell model. Treatment of human proximal tubule epithelial cells with lipopolysaccharide (LPS) closely resembles pathophysiological processes during endotoxaemia, and led to increased cytokine excretion rates and cellular reactive oxygen species levels, combined with a reduced mitochondrial membrane potential and respiratory capacity. These effects were attenuated by dexamethasone. Dexamethasone specifically increased the expression and activity of mitochondrial complex V (CV), which could not be explained by an increase in mitochondrial mass. Finally, we demonstrated that dexamethasone acidified the intracellular milieu and consequently reversed LPS-induced alkalisation, leading to restoration of the mitochondrial function. This acidification also provides an explanation for the increase in CV expression, which is expected to compensate for the inhibitory effect of the acidified environment on this complex. Besides the mechanistic insights into the beneficial effects of dexamethasone during renal cellular inflammation, our work also supports a key role for mitochondria in this process and, hence, provides novel therapeutic avenues for the treatment of AKI.


Subject(s)
Dexamethasone/pharmacology , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Kidney Tubules, Proximal/drug effects , Kidney Tubules, Proximal/metabolism , Mitochondria/drug effects , Mitochondria/metabolism , Nephritis, Interstitial/metabolism , Biomarkers , Cell Line , Cells, Cultured , Citrate (si)-Synthase/metabolism , Endotoxemia/etiology , Endotoxemia/metabolism , Endotoxemia/pathology , Epithelial Cells/pathology , Humans , Hydrogen-Ion Concentration , Intracellular Space/metabolism , Kidney Tubules, Proximal/pathology , Lipopolysaccharides/adverse effects , Membrane Potential, Mitochondrial/drug effects , Metabolic Networks and Pathways/drug effects , Nephritis, Interstitial/etiology , Nephritis, Interstitial/pathology , Reactive Oxygen Species/metabolism
9.
Eur J Clin Pharmacol ; 72(6): 725-30, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26979520

ABSTRACT

PURPOSE: Concomitant treatment with the glucose-lowering drug metformin and the platelet aggregation inhibitor dipyridamole often occurs in patients with type 2 diabetes mellitus who have suffered a cerebrovascular event. The gastrointestinal uptake of metformin is mediated by the human equilibrative nucleoside transporter 4 (ENT4), which is inhibited by dipyridamole in preclinical studies. We hypothesized that dipyridamole lowers the plasma exposure to metformin. METHODS: Eighteen healthy volunteers (mean age 23 years; 9 male) were randomized in an open-label crossover study. Subjects were allocated to treatment with metformin 500 mg twice daily in combination with dipyridamole slow-release 200 mg twice daily or to metformin alone for 4 days. After a washout period of 10 days, the volunteers were crossed over to the alternative treatment arm. Blood samples were collected during a 10-h period after intake of the last metformin dose. The primary endpoint was the area under the plasma concentration-time curve (AUC0-12h) and the maximum plasma metformin concentration (C max). RESULTS: In healthy subjects, dipyridamole did not significantly affect Cmax nor AUC0-12h of metformin under steady-state conditions. CONCLUSIONS: Previous in vitro studies report that dipyridamole inhibits the ENT4 transporter that mediates gastrointestinal uptake of metformin. In contrast, co-administration of dipyridamole at therapeutic dosages to healthy volunteers does not have a clinically relevant effect on metformin plasma steady-state exposure. This observation is reassuring for patients who are treated with this combination of drugs.


Subject(s)
Dipyridamole/pharmacology , Hypoglycemic Agents/pharmacokinetics , Metformin/pharmacokinetics , Platelet Aggregation Inhibitors/pharmacology , Adult , Cross-Over Studies , Dipyridamole/adverse effects , Equilibrative Nucleoside Transport Proteins/antagonists & inhibitors , Equilibrative Nucleoside Transport Proteins/metabolism , Female , Healthy Volunteers , Humans , Hypoglycemic Agents/adverse effects , Hypoglycemic Agents/blood , Male , Metformin/adverse effects , Metformin/blood , Platelet Aggregation Inhibitors/adverse effects , Young Adult
10.
Antimicrob Agents Chemother ; 59(6): 3233-9, 2015.
Article in English | MEDLINE | ID: mdl-25801554

ABSTRACT

Nutritional status may have a profound impact on the pharmacokinetics of drugs, yet only few data are available for tuberculosis (TB) drugs. As malnutrition occurs frequently among TB patients, we assessed the effect of malnutrition on the steady-state pharmacokinetics of total and protein-unbound rifampin during the intensive phase of TB treatment. In a descriptive pharmacokinetic study in Bandung, Indonesia, patients received a fixed standard rifampin dose of 450 mg once daily during the intensive phase of TB treatment. A full pharmacokinetic curve for rifampin was recorded, and total and unbound concentrations of rifampin were analyzed in all samples. Rifampin pharmacokinetic parameters were compared between severely malnourished (BMI of <16.0 kg/m(2)), malnourished (BMI of <18.5 kg/m(2)), and well-nourished (BMI of ≥18.5 kg/m(2)) individuals. No difference in total and protein-unbound pharmacokinetic parameters between severely malnourished (n = 7), malnourished (n = 11), and well-nourished (n = 25) patients could be demonstrated. In addition, no significant correlation between BMI and exposure (area under the concentration-time curve from 0 to 24 h [AUC0-24] and maximum concentration of drug in serum [Cmax]) was found. Females had significantly higher total AUC0-24 (geometric mean, 59.2 versus 48.2 h · mg/liter; P = 0.02) and higher unbound AUC0-24 (geometric mean, 6.2 versus 4.8 h · mg/liter; P = 0.02) than males. Overall, a marked 2-fold interindividual variation in the free fraction was observed (7.6 to 15.0%; n = 36). Nutritional status and BMI do not appear to have a major effect on total and protein-unbound pharmacokinetic parameters of rifampin in Indonesian subjects. The large interindividual variability in the free fraction of rifampin suggests that protein-unbound rather than total rifampin concentrations should preferably be used to study exposure-response relationships.


Subject(s)
Antitubercular Agents/pharmacokinetics , Antitubercular Agents/therapeutic use , Malnutrition/metabolism , Malnutrition/physiopathology , Rifampin/pharmacokinetics , Tuberculosis/blood , Tuberculosis/drug therapy , Adolescent , Adult , Body Mass Index , Drug Administration Schedule , Female , Humans , Indonesia , Male , Middle Aged , Rifampin/therapeutic use , Young Adult
11.
Drug Metab Dispos ; 41(3): 592-601, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23248200

ABSTRACT

Organic anion-transporting polypeptide 1B1 (OATP1B1) is an important hepatic uptake transporter, of which the polymorphic variant OATP1B1*15 (Asn130Asp and Val174Ala) has been associated with decreased transport activity. Rosuvastatin is an OATP1B1 substrate and often concomitantly prescribed with oral antidiabetics in the clinic. The aim of this study was to investigate possible drug-drug interactions between these drugs at the level of OATP1B1 and OATP1B1*15. We generated human embryonic kidney (HEK)293 cells stably overexpressing OATP1B1 or OATP1B1*15 that showed similar protein expression levels of OATP1B1 and OATP1B1*15 at the cell membrane as measured by liquid chromatography-tandem mass spectrometry. In HEK-OATP1B1*15 cells, the V(max) for OATP1B1-mediated transport of E(2)17ß-G (estradiol 17ß-d-glucuronide) was decreased >60%, whereas K(m) values (Michaelis constant) were comparable. Uptake of rosuvastatin in HEK-OATP1B1 cells (K(m) 13.1 ± 0.43 µM) was nearly absent in HEK-OATP1B1*15 cells. Interestingly, several oral antidiabetics (glyburide, glimepiride, troglitazone, pioglitazone, glipizide, gliclazide, and tolbutamide), but not metformin, were identified as significant inhibitors of the OATP1B1-mediated transport of rosuvastatin. The IC(50) values for inhibition of E(2)17ß-G uptake were similar between OATP1B1 and OATP1B1*15. In conclusion, these studies indicate that several oral antidiabetic drugs affect the OATP1B1-mediated uptake of rosuvastatin in vitro. The next step will be to translate these data to the clinical situation, as it remains to be established whether the studied oral antidiabetics indeed affect the clinical pharmacokinetic profile of rosuvastatin in patients.


Subject(s)
Fluorobenzenes/metabolism , Hypoglycemic Agents/metabolism , Hypoglycemic Agents/pharmacology , Organic Anion Transporters/antagonists & inhibitors , Pyrimidines/metabolism , Sulfonamides/metabolism , Administration, Oral , Chromatography, Liquid , Dose-Response Relationship, Drug , Drug Interactions , Estradiol/analogs & derivatives , Estradiol/metabolism , HEK293 Cells , Humans , Hypoglycemic Agents/administration & dosage , Kinetics , Liver-Specific Organic Anion Transporter 1 , Organic Anion Transporters/genetics , Organic Anion Transporters/metabolism , Rosuvastatin Calcium , Tandem Mass Spectrometry , Transfection
12.
Clin Pharmacol Ther ; 89(4): 587-94, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21368750

ABSTRACT

Thiazolidinediones (TZDs) are associated with fluid retention that has been suggested to be resistant to treatment with loop diuretics. This resistance is thought to be caused by upregulation of renal epithelial sodium channels (ENaCs). In this study, we tested whether these mechanisms are of clinical significance. We conducted a well-controlled study in 12 insulin-resistant nondiabetic participants, who received treatment for 9 weeks with either rosiglitazone at a dosage of 4 mg b.i.d. or placebo. The aim of the study was to investigate whether upregulation of ENaCs by rosiglitazone reduces furosemide's natriuretic response and enhances the response to the ENaC inhibitor amiloride. The natriuretic response to furosemide and amiloride and the amount of α-ENaC in urinary exosomes were quantified. Rosiglitazone neither reduced furosemide-induced natriuresis nor changed furosemide's concentration-effect curve. Furthermore, rosiglitazone did not change either amiloride-induced natriuresis nor the amount of urinary α-ENaC. This study challenges previous findings regarding TZD-related ENaC upregulation and suggests that TZD-induced fluid retention should respond normally to loop diuretics.


Subject(s)
Diuretics/pharmacology , Epithelial Sodium Channels/drug effects , Hypoglycemic Agents/pharmacology , Insulin Resistance , Thiazolidinediones/pharmacology , Adult , Amiloride/pharmacokinetics , Amiloride/pharmacology , Cross-Over Studies , Double-Blind Method , Drug Interactions , Epithelial Sodium Channels/metabolism , Exosomes/metabolism , Female , Furosemide/pharmacokinetics , Furosemide/pharmacology , Humans , Kidney/drug effects , Kidney/metabolism , Male , Middle Aged , Natriuresis/drug effects , Rosiglitazone , Up-Regulation/drug effects
13.
J Cell Mol Med ; 13(4): 712-25, 2009 Apr.
Article in English | MEDLINE | ID: mdl-18410527

ABSTRACT

Fibroblast apoptosis plays a crucial role in normal and pathological scar formation and therefore we studied whether the putative apoptosis-inducing factor curcumin affects fibroblast apoptosis and may function as a novel therapeutic. We show that 25-microM curcumin causes fibroblast apoptosis and that this could be inhibited by co-administration of antioxidants N-acetyl-l-cysteine (NAC), biliverdin or bilirubin, suggesting that reactive oxygen species (ROS) are involved. This is supported by our observation that 25-microM curcumin caused the generation of ROS, which could be completely blocked by addition of NAC or bilirubin. Since biliverdin and bilirubin are downstream products of heme degradation by heme oxygenase (HO), it has been suggested that HO-activity protects against curcumin-induced apoptosis. Interestingly, exposure to curcumin maximally induced HO-1 protein and HO-activity at 10-15 microM, whereas, at a concentration of >20-microM curcumin HO-1-expression and HO-activity was negligible. NAC-mediated inhibition of 25-microM curcumin-induced apoptosis was demonstrated to act in part via restored HO-1-induction, since the rescuing effect of NAC could be reduced by inhibiting HO-activity. Moreover pre-induction of HO-1 using 5-microM curcumin protected fibroblasts against 25-microM curcumin-induced apoptosis. On a functional level, fibroblast-mediated collagen gel contraction, an in vitro wound contraction model, was completely prevented by 25-microM curcumin, while this could be reversed by co-incubation with NAC, an effect that was also partially HO-mediated. In conclusion, curcumin treatment in high doses (>25 microM) may provide a novel way to modulate pathological scar formation through the induction of fibroblast apoptosis, while antioxidants, HO-activity and its effector molecules act as a possible fine-tuning regulator.


Subject(s)
Apoptosis/drug effects , Cicatrix/enzymology , Curcumin/pharmacology , Fibroblasts/cytology , Fibroblasts/enzymology , Heme Oxygenase (Decyclizing)/metabolism , Wound Healing/drug effects , Acetylcysteine/pharmacology , Antioxidants/pharmacology , Bilirubin/pharmacology , Collagen/metabolism , Dermis/cytology , Dose-Response Relationship, Drug , Fibroblasts/drug effects , Gels , Glutathione/pharmacology , Humans , Reactive Oxygen Species/metabolism
14.
Br J Pharmacol ; 155(7): 1066-75, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18724382

ABSTRACT

BACKGROUND AND PURPOSE: The xanthine oxidase inhibitors allopurinol and oxypurinol are used to treat hyperuricaemia, whereas loop and thiazide diuretics can cause iatrogenic hyperuricaemia. Some uricosuric drugs and salicylate have a bimodal action on urate renal excretion. The mechanisms of action of these hypo- and hyperuricaemic drugs on the handling of urate in renal tubules have not been fully elucidated. Recently, we identified the multidrug resistance protein (MRP) 4 as a luminal efflux transporter for urate in the proximal tubule. EXPERIMENTAL APPROACH: Here, we studied the effect of these drugs on [(14)C]urate transport using human embryonic kidney 293 cells overexpressing human MRP4 and in membrane vesicles isolated from these cells. KEY RESULTS: Allopurinol stimulated MRP4-mediated cellular urate efflux and allopurinol and oxypurinol both markedly stimulated urate transport by MRP4 in membrane vesicles. Bumetanide and torasemide had no effect, whereas furosemide, chlorothiazide, hydrochlorothiazide, salicylate, benzbromarone and sulfinpyrazone inhibited urate transport, at concentrations ranging from nanomolar up to millimolar. Probenecid stimulated urate transport at 0.1 microM and inhibited transport at higher concentrations. CONCLUSIONS AND IMPLICATIONS: These data suggest that inhibition of MRP4-mediated urate efflux by furosemide and thiazide diuretics could have an important function in their hyperuricaemic mechanisms. Furthermore, stimulation of MRP4-mediated renal urate efflux could be a new mechanism in the hypouricaemic action of allopurinol and oxypurinol. In conclusion, MRP4 may provide a potential target for drugs affecting urate homoeostasis, which needs to be further evaluated in vivo.


Subject(s)
Diuretics/pharmacology , Multidrug Resistance-Associated Proteins/drug effects , Uric Acid/metabolism , Uricosuric Agents/pharmacology , Allopurinol/administration & dosage , Allopurinol/pharmacology , Biological Transport/drug effects , Cell Line , Diuretics/administration & dosage , Dose-Response Relationship, Drug , Drug Delivery Systems , Homeostasis/drug effects , Humans , Multidrug Resistance-Associated Proteins/metabolism , Oxypurinol/administration & dosage , Oxypurinol/pharmacology , Salicylates/administration & dosage , Salicylates/pharmacology , Uricosuric Agents/administration & dosage
15.
Kidney Int ; 73(2): 220-5, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17978814

ABSTRACT

The Breast Cancer Resistance Protein (BCRP/ABCG2) is a transporter restricting absorption and enhancing excretion of many compounds including anticancer drugs. This transporter is highly expressed in many tissues; however, in human kidney, only the mRNA was found in contrast to the mouse kidney, where the transporter is abundant. In bcrp/abcg2((-/-)) mice, the expression of two sterol transporter genes, abcg5 and abcg8, was strongly increased in the kidney, perhaps as a compensatory mechanism to upregulate efflux. We found using immunohistochemical analysis clear localization of BCRP/ABCG2 to the proximal tubule brush border membrane of the human kidney comparable to that of other ABC transporters such as P-glycoprotein/ABCB1, MRP2/ABCC2, and MRP4/ABCC4. Hoechst 33342 dye efflux from primary human proximal tubule cells was significantly reduced by the BCRP/ABCG2 inhibitors fumitremorgin C and nelfinavir. Our study shows that in addition to other apical ABC transporters, BCRP/ABCG2 may be important in renal drug excretion.


Subject(s)
ATP-Binding Cassette Transporters/genetics , Kidney Tubules, Proximal/metabolism , Neoplasm Proteins/genetics , ATP Binding Cassette Transporter, Subfamily G, Member 2 , ATP-Binding Cassette Transporters/analysis , ATP-Binding Cassette Transporters/physiology , Animals , Cell Membrane/chemistry , Cell Membrane/metabolism , Humans , Immunohistochemistry , Kidney Tubules, Proximal/chemistry , Kidney Tubules, Proximal/cytology , Mice , Multidrug Resistance-Associated Protein 2 , Neoplasm Proteins/analysis , Neoplasm Proteins/physiology , Polymerase Chain Reaction , RNA, Messenger/analysis , Rats
16.
Kidney Int ; 72(10): 1233-41, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17851469

ABSTRACT

The multidrug resistance gene 1 product, P-glycoprotein (P-gp), is expressed in several excretory organs, including the apical membrane of proximal tubules. After inducing acute renal failure, P-gp expression is upregulated and this might be a protective function by pumping out toxicants and harmful products of oxidative stress. We characterized renal function of P-gp knockout mice and studied its consequences in renal ischemic damage. Compared with wild-type mice, knockout mice have a lower glomerular filtration rate and renal plasma flow. An augmented urinary excretion of sodium, numerous amino acids, calcium, glucose, and low molecular weight proteins was observed along with an increased diuresis. A higher lithium plasma clearance in the knockout mice suggested proximal tubular dysfunction. Electron microscopy showed mitochondrial abnormalities in proximal tubular cells that could account for decreased adenosine triphosphate levels in the cortex. After inducing ischemia, wild-type mice showed a decrease in creatinine clearance and severe proximal tubular necrosis. In contrast, knockout mice had no signs of tubular damage. Our data indicate that P-gp knockout mice have impaired renal function but are protected against ischemic renal injury.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/deficiency , Ischemia/prevention & control , Kidney Tubules, Proximal/physiopathology , Acute Kidney Injury/physiopathology , Amino Acids/urine , Animals , Calcium/urine , Diuresis , Fluorescent Antibody Technique , Glomerular Filtration Rate/genetics , Glycosuria , Immunohistochemistry , Ischemia/etiology , Kidney Tubules, Proximal/ultrastructure , Male , Mice , Mice, Inbred Strains , Mice, Knockout , Mitochondria/pathology , Mitochondria/ultrastructure , Proteinuria , Renal Circulation/genetics , Sodium/urine
17.
Cryobiology ; 54(3): 258-64, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17391662

ABSTRACT

It has now been firmly established that, not only ischemia/reperfusion, but also cold itself causes damage during kidney transplantation. Iron chelators or anti-oxidants applied during the cold plus rewarming phase are able to prevent this damage. At present, it is unknown if these measures act only during the cold, or whether application during the rewarming phase also prevents damage. We aimed to study this after cold normoxic and hypoxic conditions. LLC-PK1 cells were incubated at 4 degrees C in Krebs-Henseleit buffer for 6 or 24h, followed by 18 or 6h rewarming, respectively. Cold preservation was performed under both normoxic (95% air/5% CO2) and hypoxic (95% N2/5% CO2) conditions. The iron chelator 2,2'-DPD (100 microM), anti-oxidants BHT (20 microM) or sibilinin (200 microM), and xanthine oxidase inhibitor allopurinol (100 microM) were added during either cold preservation plus rewarming, or rewarming alone. Cell damage was assessed by LDH release (n=3-9). Addition of 2,2'-DPD and BHT during cold hypoxia plus rewarming did, but during rewarming alone did not prevent cell damage. When added during rewarming after 6h cold normoxic incubation, BHT and 2,2'-DPD inhibited rewarming injury compared to control (p<0.05). Allopurinol did not prevent cell damage in any experimental set-up. Our data show that application of iron chelators or anti-oxidants during the rewarming phase protects cells after normoxic but not hypoxic incubation. Allopurinol had no effect. Since kidneys are hypoxic during transplantation, measures aimed at preventing cold-induced and rewarming injury should be taken during the cold.


Subject(s)
Antioxidants/pharmacology , Iron Chelating Agents/pharmacology , Organ Preservation Solutions/pharmacology , Organ Preservation/methods , 2,2'-Dipyridyl/pharmacology , Allopurinol/pharmacology , Animals , Butylated Hydroxytoluene/pharmacology , Ethanol/pharmacology , Hypoxia/pathology , Hypoxia/physiopathology , L-Lactate Dehydrogenase/metabolism , LLC-PK1 Cells/drug effects , Reperfusion Injury/prevention & control , Rewarming/methods , Silybin , Silymarin/pharmacology , Sodium Hydroxide/pharmacology , Swine
18.
J Mater Sci Mater Med ; 17(10): 919-27, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16977389

ABSTRACT

In this study, the release of rhBMP-2 loaded porous Ca-P cement was studied in vitro and in vivo. We hypothesized that adsorption sites of Ca-P ceramic with high affinity for rhBMP-2 can be blocked by pretreatment of the ceramic with albumin prior to rhBMP-2 loading, which would result in weaker rhBMP-2 binding and enhanced release of rhBMP-2. Preset porous Ca-P cement discs with a diameter of 6.35 mm (volume: 75 mm3) were pretreated by incubation in a solution of 10% rat serum albumin for 24 h or in ddH2O (control group) prior to administration of 5 mug radiolabeled 131I-rhBMP-2. Release was assessed in vitro in phosphate buffered saline (PBS) and fetal calf serum and in vivo by longitudinal scintigraphic imaging of radiolabeled 131I-rhBMP-2 and gamma counting of dissected implants. In vitro release from pretreated discs was higher during the first day. For both formulations, release in PBS was limited compared to release in serum. In vivo release considerably exceeded in vitro release. In vivo release kinetics showed no significant difference of half-lives between pretreated and control discs. Both formulations showed sustained release during at least 4 weeks. Ex vivo gamma counting of retrieved samples confirmed scintigraphic results and showed that the capsule and surrounding tissues only contained a minor fraction rhBMP-2. We conclude that 1. scintigraphy of 131I-labeled rhBMP-2 provides a reliable method for longitudinal measurement of rhBMP-2 release kinetics in vivo. 2. albumin pretreatment of porous Ca-P cement does not results in relevant increase of initial release of rhBMP-2 in vivo, and 3. preset rhBMP-2 loaded porous Ca-P cement discs exhibit one phase exponential release kinetics in the rat ectopic model, characterized by a retention of 20-30% after 4 weeks.


Subject(s)
Albumins , Biocompatible Materials , Bone Morphogenetic Proteins/administration & dosage , Calcium Phosphates , Drug Delivery Systems , Recombinant Proteins/administration & dosage , Transforming Growth Factor beta/administration & dosage , Animals , Bone Morphogenetic Protein 2 , Male , Rats , Rats, Sprague-Dawley
19.
Kidney Int ; 69(12): 2186-93, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16612327

ABSTRACT

Renal ATP binding cassette (ABC) transporters have an important role in the elimination of metabolic waste products and compounds foreign to the body. The kidney has the ability to tightly control the expression of these efflux transporters to maintain homeostasis, and as a major mechanism of adaptation to environmental stress. In the present study, we investigated the expression of 45 ABC transporter genes in the mouse kidney under basal conditions, after induction of ischemia and after regeneration. Two days after clamping, mice showed a 76% decrease in renal creatinine clearance, which improved clearly within 7 days. This was confirmed by histological examinations. Seven days after ischemia, real-time quantitative Polymerase chain reaction data showed that transcript abundance of abcb1, abcb11, and abcc4 was increased, and that of abca3, abcc2, and abcg2 decreased. Expression of all transporters returned to baseline after 14 days, except for abcb11, which was reduced. Abcb11 is the major liver canalicular bile salt export pump. Here we show for the first time expression in the kidney and localization of the transporter to the apical membrane of proximal tubules. The presence of another novel renal transporter, abca3, was confirmed by Western blotting. Immunohistochemistry showed that abca3 is localized to the peritubular capillaries and apical membrane of proximal tubules. In conclusion, after inducing ischemic reperfusion injury in the kidney, ABC transporters appear to be differentially regulated, which might be associated with the renal regeneration process. Furthermore, we showed for the first time expression and subcellular localization of abcb11 and abca3 in mouse kidney.


Subject(s)
ATP-Binding Cassette Transporters/genetics , Gene Expression Profiling , Kidney/pathology , Reperfusion Injury/genetics , Reperfusion Injury/pathology , ATP Binding Cassette Transporter, Subfamily B , ATP Binding Cassette Transporter, Subfamily B, Member 1 , ATP Binding Cassette Transporter, Subfamily B, Member 11 , ATP Binding Cassette Transporter, Subfamily G, Member 2 , ATP-Binding Cassette Transporters/analysis , ATP-Binding Cassette Transporters/biosynthesis , Animals , Blotting, Western , Gene Expression Regulation , Immunohistochemistry , Kidney/chemistry , Kidney Tubules, Proximal/chemistry , Kidney Tubules, Proximal/pathology , Male , Membrane Transport Proteins/analysis , Membrane Transport Proteins/genetics , Mice , Mice, Inbred Strains , Multidrug Resistance-Associated Protein 2 , Multidrug Resistance-Associated Proteins/analysis , Multidrug Resistance-Associated Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction
20.
J Control Release ; 106(1-2): 162-71, 2005 Aug 18.
Article in English | MEDLINE | ID: mdl-15972241

ABSTRACT

The release kinetics of recombinant human bone morphogenetic protein-2 (rhBMP-2) loaded poly(dl-lactic-co-glycolic acid)/calcium phosphate cement (PLGA/Ca-P cement) composites were studied in vivo. RhBMP-2 was radiolabeled with (131)I and entrapped within PLGA microparticles or adsorbed onto the microparticle surface. PLGA microparticles were prepared of high molecular weight (HMW) PLGA (weight average molecular weight [M(w)] 49,100+/-1700) or low molecular weight (LMW) PLGA (M(w) 5,900+/-300) and used for preparation of 30:70 wt.% PLGA/Ca-P cement composite discs. Release of 131I-rhBMP-2 loaded composites was assessed by scintigraphic imaging according to a 2(2) two-level full factorial design in the rat ectopic model during four weeks. In vivo release kinetics varied among formulations. All formulations showed slow release without initial burst, and displayed a linear release from 3 to 28 days. Release of LMW entrapped rhBMP-2 composites (1.7+/-0.3%/day) was significantly faster than release from other formulations (p<0.01). After 28 days, retention within the composites was 65+/-5%, 75+/-4%, 50+/-4% and 70+/-6% of the initial rhBMP-2 for HMW entrapped, HMW adsorbed, LMW entrapped and LMW adsorbed rhBMP-2 composites, respectively. Release from the composite was probably slowed down by an interaction of rhBMP-2 and Ca-P cement after rhBMP-2 release from PLGA microparticles. We conclude that PLGA/Ca-P cement composites can be considered as sustained slow release vehicles and that the release and retention of rhBMP-2 can be modified according to the desired profile to a limited extent.


Subject(s)
Bone Cements , Bone Morphogenetic Proteins/administration & dosage , Calcium Phosphates/chemistry , Glycolates/chemistry , Recombinant Proteins/administration & dosage , Transforming Growth Factor beta/administration & dosage , Adsorption , Animals , Biocompatible Materials , Bone Morphogenetic Protein 2 , Bone Morphogenetic Proteins/chemistry , Bone Morphogenetic Proteins/pharmacokinetics , Delayed-Action Preparations , Drug Carriers , Lactic Acid , Male , Microspheres , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Rats , Rats, Sprague-Dawley , Recombinant Proteins/chemistry , Recombinant Proteins/pharmacokinetics , Transforming Growth Factor beta/chemistry , Transforming Growth Factor beta/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...